

MAXIM.026C3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Hellstrand, et al.	)	Group Art Unit: Unknown
			)	
App. No.	:	Unknown	)	
			)	
Filed	:	Herewith	)	
			)	
For	:	ENHANCED ACTIVATION OF	)	
		NATURAL KILLER CELLS	)	
		USING AN NK CELL	)	
		ACTIVATOR AND A	)	
		HYDROGEN PEROXIDE	)	
		SCAVENGER OR INHIBITOR	)	
			)	
Examiner	:	Unknown	)	
			)	

---

31046 U.S. PTO  
10/076306  
02/12/02

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office  
PO Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references which were previously disclosed and/or cited by the Applicants in the prosecution in related applications hereto, U.S. Application No. 09/516,641, filed March 1, 2000, which is a continuation of U.S. Application No. 08/681,108, filed July 22, 1996, now U.S. Patent No. 6,071,509, which is a continuation of 08/287,200, filed August 8, 1994, now abandoned. The present application claims the priority date of the parent of this continuation application, Application No. 08/287,200, under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).


Appl. No. : Unknown  
Filed : Herewith

This Information Disclosure Statement is being filed within three months of the filing date of this application, and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Feb. 12, 2002

By:   
AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(619) 235-8550

S:\DOCS\MKD\MKD-2497.DOC\021202

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown	11046 U.S. PTO 10/076306 02/12/02
	APPLICANT Hellstrand, et al.		
	FILING DATE February 12, 2002	GROUP Unknown	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	5,348,739	09-1994	Hellstrand et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	JP 7-165582	06/27/95	Japan (with English translation in 15 pages)				
	WO 93/24144	12/09/93	Patent Cooperation Treaty				
	0 247 613 A2	12/02/87	European Patent Office				

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	
	Abrams, et al., "Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes," <i>The Journal of Immunology</i> 132: No. 6, 3192-3196, June 1984.
	Abrams, et al., "igh-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," <i>Journal of the National Cancer Institute</i> , 82: No. 14, 1202-1206, July 18, 1990.
	Alam, et al., "Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN- , Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor- , and Histamine-Releasing Factors on the Secretion of Histamine From Basophils," <i>The Journal of Immunology</i> , 142: No. 10, 3431-3435, May 18, 1989.
	Abrams, et al., "Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes," <i>The Journal of Immunology</i> 132: No. 6, 3192-3196, June 1984.
	Abrams, et al., "igh-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," <i>Journal of the National Cancer Institute</i> , 82: No. 14, 1202-1206, July 18, 1990.
	Alam, et al., "Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN- , Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor- , and Histamine-Releasing Factors on the Secretion of Histamine From Basophils," <i>The Journal of Immunology</i> , 142: No. 10, 3431-3435, May 18, 1989.
	Baker, et al., "Chondrocyte Antioxidant Defenses: The Roles of Catalase and Glutathione Peroxidase in Protection Against H <sub>2</sub> O <sub>2</sub> Dependent Inhibition of Proteoglycan Biosynthesis," <i>The Journal of Rheumatology</i> , 15: No. 4, 670-677, 1988.
	Barna, et al., "Tumor-Enhancing Effects of Cimetidine," <i>Oncology</i> , 40: 43-45, (1983).
	Beer, et al., The Influence of Histamine on Immune and Inflammatory Responses, <i>Advances in Immunology</i> , 35: 209-268 (1984).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Brune, et al., "Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia," <i>British Journal of Haematology</i> , 92:620-626 (1996).
	Budd, et al., "Phase I Trial of High-Dose Bolus Interleukin-2 and Interferon Alfa-2a in Patients With Metastatic Malignancy," <i>Journal of Clinical Oncology</i> , 10: No. 5, 804-809, May 1992.
	Burtin, et al., "Clinical Improvement in Advanced Cancer Disease After Treatment Combining Histamine and H2-Antihistaminics" (Ranitidine or Cimetidine), Accepted June 1987.
	Burtin, et al., "The Influence of Intraperitoneal Injections of Histamine on Tumour Growth in Fibrosarcoma-Bearing Mice", <i>Cancer Letters</i> , 12: 195-201, (1981).
	Chaudhri, et al., "Antioxidants Inhibit Proliferation and Cell Surface Expression of Receptors for Interleukin-2 and Transferrin in T Lymphocytes Stimulated with Phorbol Myristate Acetate and Ionomycin" <i>Cellular Immunology</i> , 115:204-213 (1988).
	Chehimi, et al., "Natural Killer (NK) Cell Stimulatory Factor Increases the Cytotoxic Activity of NK Cells from Both Healthy Donors and Human Immunodeficiency Virus-infected Patients," <i>Journal of Experimental Medicine</i> , 175: 789-796, March 1992.
	Ching, et al., "In vitro Methods for Screening Agents with an Indirect Mechanism of Antitumour Activity: Xanthenone Analogues of Flavone Acetic Acid," <i>Eur. J. Cancer</i> , 27: No. 12, 1684-1689, 1991.
	Ching, et al., "Induction of Natural Killer Activity by Xanthenone Analogues of Flavone Acetic Acid: Relation with Antitumour Activity," <i>Eur. J. Cancer</i> , 27: No. 1, 79-83, 1991.
	Damia, et al., "Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells," <i>Cancer Immunol Immunother</i> , 32: 241-244, 1990.
	Davies, et al., "Interactions between human monocytes and tumor cells. Monocytes can either enhance or inhibit the growth and survival of K562 Cells," November 1991.
	Dempsey, et al., "The Differential Effects of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor, T Cell Growth Factor, and Interferon on Human Natural Killer Activity," <i>The Journal of Immunology</i> , May 17, 1982.
	Dillman, et al., "Continuous Interleukin-2 and Lymphokine-Activated Killer Cells for Advanced Cancer: A National Biotherapy Study Group Trial," <i>Journal of Clinical Oncology</i> , 9: No. 7, 1233-1240, July 1991.
	Dilman, et al., "eombinant Interleukin-2 and Adoptive Immunotherapy Alternated with Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group Trial," <i>Journal of the National Cancer Institute</i> , 82: No. 16, 1345-1348, August 15, 1990.
	Dohlsten, et al., "Histamine Inhibits Interferon- Production via Suppression of Interleukin 2 Synthesis," <i>Cellular Immunology</i> , 101: 493-501, 1986.
	Dröge, et al., "Effect of Reactive Oxygen Intermediates and Antioxidants on Proliferation and Function of T Lymphocytes" <i>Methods in Enzymology</i> , 234:135-151 (1994).
	Dröge, et al., Histamine Augments Interleukin-2 Production and the Activation of Cytotoxic T Lymphocytes, <i>Immunopharmacology</i> , 11: 1-6, 1986.
	Dutcher, et al., "A Phase II Study of High-Dose Continuous Infusion Interleukin-2 With Lymphokine-Activated Killer Cells in Patients With Metastatic Melanoma," <i>Journal of Clinical Oncology</i> , 9: No. 4, 641-648, April 1991..

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Duwe, et al., "Natural Killer Cell-Mediated Lysis Involves an Hydroxyl Radical-Dependent Step," <i>The Journal of Immunology</i> , 134: No. 4, 2637-2644, April 1985.
	El-Hag, et al., "Down-Regulation of Human Natural Killer Activity Against Tumors by the Neutrophil Myeloperoxidase System and Hydrogen Peroxide," <i>The Journal of Immunology</i> 133: No. 6, 3291-3297, December 1984.
	Froelich, et al., "Induction of lymphokine activated killer cells in serum-free medium" <i>Journal of Immunological Methods</i> , 86:205-211, No. 2 (1986).
	Galligioni, "Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with Flavone acetic acid (FAA)," <i>Annals of Oncology</i> , 2: 145-150, 1991.
	Hellstrand, "Biogenic Amines in the Regulation of Human Natural Killer Cell Cytotoxicity," 1987.
	Hellstrand, et al., "Histaminergic Regulation of NK Cells" <i>Journal of Immunology</i> , 153:4940-4947, No. 11 (1994).
	Hellstrand, et al., "A Cell-to-Cell Mediated Interaction Involving Monocytes and Non-T/CD16 <sup>+</sup> Natural Killer (NK) Cells is Required for Histamine H <sub>2</sub> -Receptor-Mediated NK-Cell Activation," <i>Scand J. Immunol</i> , 31: 631-644, 1990.
	Hellstrand, et al., "Cell-to-Cell Mediated Inhibition of Natural Killer Cell Proliferation by Monocytes and its Regulation by Histamine H <sub>2</sub> -Receptors," <i>Scand J. Immunol</i> , 34: 741-752, 1991..
	Hellstrand, et al., "Differential Effects of Histamine Receptor Antagonists on Human Natural Killer Cell Activity," <i>Int. Archs Allergy appl. Immunology</i> , 84: 247-255, 1987.
	Hellstrand, et al., "Enhancement of Human Natural Killer Cell Cytotoxicity by Serotonin: Role of Non-T/CD16 <sup>+</sup> NK Cells, Accessory Monocytes, and 5-HT <sub>1A</sub> Receptors," <i>Cellular Immunology</i> , 127: 199-214, 1990.
	Hellstrand, et al., "Histamine H <sub>2</sub> -Receptor-Mediated Regulation of Human Natural Killer Cell Activity," <i>The Journal of Immunology</i> , 137: No. 2, July 15, 1986.
	Hellstrand, et al., "Monocyte-Induced Down-Modulation of CD16 and CD56 Antigens on Human Natural Killer Cells and its Regulation by Histamine H <sub>2</sub> -Receptors," <i>Cellular Immunology</i> , 138: 44-45, 1991..
	Hellstrand, et al., "Monocyte-Mediated Suppression of IL-2-Induced NK-Cell Activation," <i>Scand J. Immunol</i> , 32: 183-192, 1990.
	Hellstrand, et al., "Regulation of the Natural Killer Cell Response to Interferon- by Biogenic Amines," <i>Journal of Interferon Research</i> , 12: 199-206, 1992.
	Hellstrand, et al., "Role of Histamine in Natural Killer Cell-Mediated Resistance Against Tumor Cells," <i>The Journal of Immunology</i> , 145: No. 12, December 15, 1990.
	Hellstrand, et al., "Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity," <i>The Journal of Immunology</i> , 139: No. 3, August 1, 1987
	Hellstrand, et al., "Serotonergic 5-HT <sub>1A</sub> Receptors Regulate a Cell Contact-Mediated Interaction between Natural Killer Cells and Monocytes," <i>Scand J. Immunol</i> , 37: 7-18, 1993
	Hellstrand, et al., "Histaminergic Regulation of NK Cells" <i>Journal of Immunology</i> , 153:4940-4947, No. 11 (1994).
	Hellstrand, et al., "Suppression of human natural killer cell cytotoxicity by interleukin-2," <i>Clin. Exp. Immunol</i> , 77: 410-416, 1989

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Hellstrand, et al., "Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and Interleukin-2," <i>Int. Arch. Allergy Appl. Immunology</i> , 92: 379-389, 1990.
	Histamine augments interleukin-2 production and the activation of cytotoxic T lymphocytes, <i>Chemical Abstracts</i> , 104: Number 146898m, page 146891.
	Hornung, et al., "Augmentation of Natural Killer Activity, Induction of IFN and Development Tumor Immunity During the Successful Treatment of Established Murine Renal Cancer Using Flavone Acetic Acid and IL-2," <i>The Journal of Immunology</i> , 141: No. 10, 3671-3679, November 15, 1988.
	Huwylar, et al., "Effect of Ascorbic Acid on Human Natural Killer Cells," <i>Immunology Letters</i> , 10: 173-176, 1985.
	Ilson, et al., "A Phase II Trial of Interleukin-2 and Interferon Alfa-2a in Patients With Advanced Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 7, 1124-1130, July 1992.
	Kendall A. Smith, "Interleukin-2: Inception, Impact, and Implications," <i>Science</i> , 240: 1169-1176, May 27, 1988.
	Kessel, et al., "Cytotoxicity by human adherent cells: oxygen-dependent and -independent cytotoxic reactions by different cell populations," <i>Immunology</i> , 58: 291-296, 1986.
	Khoo, et al., "Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2," <i>Clin. Exp. Metastasis</i> , 10: 239-252, 1992.
	Krigel, et al., "renal Cell Carcinoma: Treatment With Recombinant Interleukin-2 Plus Beta-Interferon," <i>Journal of Clinical Oncology</i> , 8: No. 3, 460-467, March 1990.
	Lasek, et al., "Potentiation of antitumor effects of tumor necrosis factor $\gamma$ and interferon (by macrophage-colony-stimulating factor in a MnB16 melanoma model in mice" <i>Cancer Immunol Immunother</i> 40:315-321 (1995).
	Lespinatas, et al., "Enhancement by serotonin of intra-tumour penetration of spleen cells," <i>Br. J. Cancer</i> , 50: 545-547, (1984).
	Los, et al., "Hydrogen peroxide as a potent activator of T lymphocyte functions" <i>Eur. Journal of Immunology</i> , 25:159-165 (1995).
	Lotze, et al., "Interleukin 2 as a Pharmacologic Reagent, Chapter 12 from the National Institutes of Health," October 28, 1988.
	Malech, et al., "Peptide derivative cytochrome inhibit enzyme system oxidation burst phagocyte cell inflammation disease" DABASE WPI/DERWENT (Abstract) (1989).
	Mavligit, et al., "plenic Versus Hepatic Artery Infusion of Interleukin-2 in Patients with Liver Metastases," <i>Journal of Clinical Oncology</i> , 8: No. 2, 319-324, 1990.
	Mertens, et al., "Sustained Indomethacin and Ranitidine with Intermittent Continuous Infusion Interleukin-2 in Advanced Malignant Melanoma: A Phase II Study," <i>Clinical Oncology</i> , 5: No. 2, 107-113, 1993.
	Middleton, et al., "Effects of Flavonoids on Immune and Inflammatory Cell Functions," <i>Biochemical Pharmacology</i> , 43: No. 6, 1167-1179, 1992.
	Munakata, et al., "Induction of Interferon- Production by Human Natural Killer Cells Stimulated by Hydrogen Peroxide," <i>The Journal of Immunology</i> , 134: No. 4, 2449-2455, April 1985.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Nabil Hanna, "The Role of Natural Killer Cells in the Control of Tumor Growth and Metastasis," <i>Biochimica et Biophysica Acta</i> , 780: 213-226, 1985.
	Nair, et al., "Histamine-Induced Suppressor Factor Inhibition of NK Cells: Reversal with Interferon and Interleukin 2," <i>The Journal of Immunology</i> , 136: No. 7, 2456-2462, April 1, 1986
	Novogrodsky, et al., "Hydroxyl radical scavengers inhibit lymphocyte mitogenesis" <i>Proc. Natl. Acad. Sci. USA</i> , 79:1171-1174 (1982).
	Okamoto, et al., "Possible involvement of adenosine 3':5'-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells," <i>Immunology</i> , 70: 186-190, 1990
	Osband, et al., "Successful Tumour Immunotherapy with Cimetidine in Mice," <i>The Lancet</i> , No. 8221, 1: 636-638 (1981).
	Østensen, et al., "Enhancement of Human Natural Killer Cell Function by the Combined Effects of Tumor Necrosis Factor or Interleukin-1 and Interferon- or Interleukin-2," <i>Journal of Biological Response Modifiers</i> , 8: 53-61, 1989.
	Phillips, et al., "Activation of Natural Killer Cells via the p75 Interleukin 2 Receptor," <i>J. Exp. Med.</i> , 170: 291-296, July 1989.
	Pignol, et al., "Role of Flavonoids in the Oxygen-Free Radical Modulation of the Immune Response," <i>Plant Flavonoids in Biology &amp; Medicine II: Biochemical, Cellular . . .</i> , 173-182, 1988.
	Rabilloud, et al., "Deficiency in Catalase Activity Correlates with the Appearance of Tumor Phenotype in Human Keratinocytes," <i>Int. J. Cancer</i> , 45: 952-956, 1990.
	Richtsmeier, et al., "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer," <i>Ann Otol Rhinol Laryngol</i> , 96: No. 5, 569-572, 1987.
	Rosenberg, "The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2," <i>Annals of Surgery</i> , 208: No. 2, 121-135, August 1988.
	Roth, et al., "Inhibition of Lymphokine-activated Killer Cell Function by Human Alveolar Macrophages," <i>Cancer Research</i> , 49: 4690-4695, September 1989.
	Saarloos, et al., "Effects of Cancer Immunotherapy with Indomethacin and Interleukin-2 on Murine Hemopoietic Stem Cells," <i>Cancer Research</i> , 52: 6452-6462, December 1, 1992.
	Saarloos, et al., "Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis," <i>Clin. Exp. Metastasis</i> , 11: 275-283, 1993.
	Salup, et al., "Chemoimmunotherapy of Metastatic Murine Renal Cell Carcinoma Using Flavone Acetic Acid and Interleukin 2," <i>The Journal of Urology</i> , 147: 1120-1123, April 1992.
	Schantz, et al., "A phase II study of interleukin-2 and interferon-alpha in head and neck cancer," <i>Investigational New Drugs</i> , 10: 217-223, 1992.
	Schleimer, et al., "Regulation of Human Basophil Mediator Release by Cytokines," <i>The Journal of Immunology</i> , 143: No. 4, 1310-1317, August 15, 1989.
	Seaman, et al., "Suppression of Natural Killing in Vitro by Monocytes and Polymorphonuclear Leukocytes," <i>The Journal of Clinical Investigation</i> , 69: 876-888, April 1982.

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.26C3	APPLICATION NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Shau, et al., "Inhibition of Lymphokine-Activated Killer- and Natural Killer-Mediated Cytotoxicities by Neutrophils," <i>The Journal of Immunology</i> , 143: No. 3, 1066-1072, August 1989.
	Siegel, et al., "The IL-2 Receptor Chain (p70): Role in Mediating Signals for LAK, NK, and Proliferative Activities," <i>Science</i> , Volume 238, October 2, 1987
	Sleijfer, et al., "Phase II Study of Subcutaneous Interleukin-2 in Unselected Patients With Advanced Renal Cell Cancer on an Outpatient Basis," <i>Journal of Clinical Oncology</i> , 10: No. 7, 1119-1123, July 1992.
	Sone, et al., "Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients" <i>Cancer Immunol Immunother.</i> 30:357-362 (1990).
	Stoter, et al., "Sequential Administration of Recombinant Human Interleukin-2 and Dacarbazine in Metastatic Melanoma: A Multicenter Phase II Study," <i>Journal of Clinical Oncology</i> , 9: No. 9, 1687-1691, September 1991.
	Suthanthiran, et al., "Hydroxyl radical scavengers inhibit human natural killer cell activity," <i>Nature</i> 307: 276-278, (1984).
	Szatrowski, et al., "Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells," <i>Cancer Research</i> , 51: 794-798, February 1991.
	Tel-Or, et al., "Hydroperoxide Metabolism in Cyanobacteria," <i>Archives of Biochemistry and Biophysics</i> , 246: No. 1, 396-402, April 1986.
	Thompson, et al., "Prolonged Continuous Intravenous Infusion Interleukin-2 and Lymphokine-Activated Killer-Cell Therapy for Metastatic Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 6, 960-968, June 1992.
	Thornes, et al., "Combination of Cimetidine with other Drugs for Treatment of Cancer," <i>New England Journal of Medicine</i> 308: 591-592, March 10, 1983.
	Tom Smith, MD, "Histamine Type 2-Receptor Antagonists and Cancer Immunotherapy," <i>Comprehensive Therapy</i> , 16: No. 1, 8-13, 1990.
	Trizzi, et al., "Immunological Effects of Flavone Acetic Acid," <i>Cancer Research</i> , 50: 6483-6485, October 15, 1990.
	Urba, et al., "Enhancement of Natural Killer Activity in Human Peripheral Blood by Flavone Acetic Acid," <i>The Journal of the National Cancer Institute</i> , 80: No. 7, 521-525, June 1, 1988.
	Weiss, et al., "A Randomized Phase II Trial of Continuous Infusion Interleukin-2 or Bolus Injection Interleukin-2 Plus Lymphokine-Activated Killer Cells for Advanced Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 2, 275-281, February 1992.
	Whitacre, et al., "Oxygen Free Radical Generation and Regulation of Proliferative Activity of Human Mononuclear Cells Responding to Different Mitogens," <i>Cellular Immunology</i> , 144: 287-295, 1992.
	Wilttrout, et al., "Flavone-8-Acetic Acid Augments Systemic Natural Killer Cell Activity and Synergizes with IL-2 for Treatment of Murine Renal Cancer," <i>The Journal of Immunology</i> , 140: No. 9, 3261-3265, May 1, 1988.

S:\DOCS\JMJ\JM-3822.DOC

051500

S:\DOCS\MKD\MKD-2500.DOC

021202

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	